Abstract
Acute myeloid leukemia (AML) is a hematological malignancy with an undefined heritable risk. Here we performed a meta-analysis of three genome-wide association studies, with replication in a fourth study, incorporating a total of 4018 AML cases and 10488 controls. We identified a genome-wide significant risk locus for AML at 11q13.2 (rs4930561; P = 2.15 × 10-8; KMT5B). We also identified a genome-wide significant risk locus for the cytogenetically normal AML sub-group (N=1287) at 6p21.32 (rs3916765; P = 1.51 × 10-10; HLA). Our results inform on AML etiology by identifying putative functional genes operating in histone methylation (KMT5B) and immune function (HLA).
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was funded by Blood Cancer UK (to JMA; #06002 and #13044). The Hungarian AML study was funded by the Hungarian National Research, Development and Innovation Office (NKFIH) (NVKP_16 1 2016 0004), a Momentum grant (LP 95021) from the Hungarian Academy of Sciences and EUs Horizon 2020 research and innovation program under grant agreement No. 739593. The KORA study was initiated and financed by the Helmholtz Zentrum Munchen, German Research Center for Environmental Health, which is funded by the German Federal Ministry of Education and Research (BMBF) and by the State of Bavaria. KORA research was supported within the Munich Center of Health Sciences (MC-Health), Ludwig-Maximilians-Universitat, as part of LMUinnovativ. The recruitment of cases via the Catholic University of Rome was funded by Progetto AIRC 5permille Mynerva. DN is an endowed Professor of the Deutsche Jose Carreras Leukaemie Stiftung (DJCLS H 03/01) and is funded by the H.W. & J. Hector fund, Baden Wuerttemberg and the Dr. Rolf M. Schwiete Fund, Mannheim.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All studies were conducted in accordance with the Declaration of Helsinki and received local institutional review board or national Research ethics committee approval was given to the Newcastle Haematology Biobank (07/H0906/109+5) and the AML genome-wide association study in the UK (06/q1108/92, BH136664 (7078)). AML cases and controls for Samples from the Hungarian AML patients were obtained during the standard diagnostic workup at the Hematology Divisions of the 1st and 3rd Department of Internal Medicine, Semmelweis University, Budapest, following ethical approval from the Local Ethical Committee (TUKEB-1552012) and the Hungarian Medical Research Council (1483-2/2017/EKU).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
AML case and control genotyping data from the UK Biobank can be obtained via application through http://www.ukbiobank.ac.uk/. Genotyping data on 2699 individuals recruited to the 1958 British Birth Cohort (Hap1.2M-Duo Custom array data) and 2501 individuals from the UK Blood Service are available from the Wellcome Trust Case Control Consortium 2 (http://www.wtccc.org.uk/;WTCCC2:EGAD00000000022, EGAD00000000024). Case and control genotyping data from 1615 individuals recruited to the KORA study can be obtained via application through https://www.helmholtz-muenchen.de/en/kora/. Other genotyping data supporting the findings of this study can be found as deposited in NCBI Gene Expression Omnibus under accession numbers GSE20672, GSE32462, GSE34542, GSE46745 and GSE46951 or from the authors on reasonable request. eQTL data is available from the eQTLGen consortium via http://www.eqtlgen.org/cis-eqtls.html. ENCODE data is available via download from ftp://hgdownload.cse.ucsc.edu/goldenPath/hg19/database/wgEncodeAwgSegmentationCombinedH1hesc.txt.gz for H1 human embryonic stem cells (H1hesc) and from ftp://hgdownload.cse.ucsc.edu/goldenPath/hg19/database/wgEncodeAwgSegmentationCombinedK562.txt.gz for K562 myeloid leukemia cells. The remaining data are contained within the supplementary files or available from the authors upon reasonable request.
